Abstract
Background Complete reporting of seroepidemiologic studies (e.g. sampling and measurement methods, immunoassay characteristics) are critical to their interpretation, comparison, and utility in evidence synthesis. The Reporting of Seroepidemiologic studies—SARS_JCoV_J2 (ROSES-S) guideline is a reporting checklist that aims to improve the quality and transparency of reporting in SARS-CoV-2 seroepidemiological studies. While the synthesis of seroepidemiologic studies played a crucial role in public health decision-making during the COVID-19 pandemic, adherence of SARS-CoV-2 seroepidemiologic studies to the ROSES-S guideline has not yet been evaluated.
Objectives To evaluate the completeness of SARS-CoV-2 seroepidemiologic study reporting over the first two years of the COVID-19 pandemic by assessing adherence to the ROSES-S reporting guideline, determine whether publication of the ROSES-S guideline was associated with changes in reporting completeness, and identify study characteristics associated with reporting completeness.
Methods A stratified random sample of SARS-CoV-2 seroepidemiologic studies from the SeroTracker living systematic review database was evaluated for adherence to the ROSES-S guideline. We categorized study adherence to each reporting item in the guideline as “reported”, “not reported”, or “not applicable”. For each reporting item we calculated the percentage of studies that were adherent. We also calculated the median and interquartile range (IQR) adherence across all items and by item domain. Piecewise and multivariable beta regression analyses were used to determine whether publication date of the ROSES-S guideline was associated with changes in the overall adherence scores and to identify study characteristics associated with overall adherence scores.
Results 199 studies were included and analyzed. The median adherence to reporting items was 48.1% (IQR 40.0%–55.2%) per study. Adherence to reporting items ranged from 8.8% to 72.7% per study. The laboratory methods domain (e.g. description of testing algorithm) had the lowest median adherence (33.3% [IQR 25.0%–41.7%%]), while the discussion domain had the highest median adherence (75.0% [IQR 50.0%–100.0%])). There were no significant changes in reporting adherence to ROSES-S before and after guideline publication. Article publication source (p<0.001), study risk of bias (p=0.001), and sampling method (p=0.004) were significantly associated with adherence to the ROSES-S guideline.
Conclusions The completeness of reporting in SARS-CoV-2 seroepidemiologic studies was suboptimal, especially in laboratory methods, and was associated with key study characteristics. Publication of the ROSES-S guideline was not associated with changes in reporting practices. Given that reporting is necessary to improve the standardization and utility of seroprevalence data in evidence synthesis, authors should improve adherence to the ROSES-S guideline with support from stakeholders.
Competing Interest Statement
No funding source had any role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit results. This manuscript does not necessarily reflect the views of the World Health Organization or any other funders.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020183634
Funding Statement
SeroTracker receives funding for SARS-CoV-2 seroprevalence study evidence synthesis from the Public Health Agency of Canada through Canada's COVID-19 Immunity Task Force, the World Health Organization Health Emergencies Programme, the Robert Koch Institute, and the Canadian Medical Association Joule Innovation Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Findings of this study are available within the article and its supplementary materials. The corresponding author may be contacted for all other requests.